News & Articles

Oxford Vacmedix appoints a Global Contract Research Organisation (CRO) to run a Phase 1 trial of immunotherapy cancer vaccine OVM-200 in the UK. Oxford, UK – 24th January 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that a leading global CRO has been appointed to run the Phase 1 trial of lead immunotherapy cancer vaccine, OVM-200. The trial will be the first time that OVM’s novel proprietary Recombinant O...

Grant will fund joint research by Imperial College, London and Oxford Vacmedix into antimicrobial resistance, in collaboration with the Ditan Hospital in Beijing, China Oxford, UK – 19th December 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today the award of an Innovate UK grant to fund research that capitalises on OVM’s proprietary recombinant overlapping peptide (ROP) technology. The research will be carrie...

Oxford Vacmedix appoints Belgium based Eurofins CDMO to carry out the GMP manufacturing of the lead immunotherapy cancer vaccine OVM-200, to support Phase 1 application. Oxford, UK – 22nd November 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Eurofins CDMO based in Belgium has been appointed to complete the GMP (Good Manufacturing Practice) manufacture of its lead immunotherapy cancer vaccine, OVM- 200....

Grant to fund research into novel applications and development of new cancer vaccines using the recombinant overlapping peptide technology developed by Dr. Shisong Jiang. Oxford, UK – 9th July 2019 Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that research into its novel Recombinant Overlapping Peptide (ROP) technology will be carried out in the Department of Oncology at the University of Oxford. The r...